Related Experiment Video
Updated: Feb 11, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Cycling Toward Progress: Ribociclib, a CDK 4/6 Inhibitor for Breast Cancer
1Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
Abstract:
Ribociclib is an orally active, highly selective inhibitor of cyclin-dependent kinase (CDK) 4 and 6. It is the second CDK 4/6 inhibitor approved for hormone receptor-positive breast cancer. The addition of ribociclib to an aromatase inhibitor has resulted in marked improvements in progression-free survival for patients with metastatic breast cancer. Clin Cancer Res; 24(13); 2981-3. ©2018 AACRSee related article by Shah et al., p. 2999.
Related Concept Videos
Dipeptidyl Peptidase 4 Inhibitors
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Inhibition of Cdk Activity
S-Cdk Initiates DNA Replication
Two states at the origin of replication
In eukaryotes, the initiation of replication occurs at many sites on the chromosomes, called the origins of...
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...

